European Journal of Endocrinology · Nov 16, 2026
GLP-1R Agonists in PMOS: Network Meta-Analysis and Drug-Target MR
By Bao F, Jin Y, Wang R et al.
Background: The reproductive-endocrine effects of GLP-1 receptor agonists (GLP-1RAs) in polyendocrine metabolic ovarian syndrome (PMOS; formerly polycystic ovary syndrome) and their relationship to metabolic improvement remain uncertain. Methods: We performed a frequentist random-effects network meta-analysis of randomized trials comparing GLP-1RA, metformin, their combination, and placebo. An adapted CINeMA assessment evaluated certainty about any difference. Exploratory meta-regressions examined metabolic-endocrine associations; drug-target Mendelian randomization (MR) examined genetically proxied GLP1R expression. Results: Forty-two reports published during 2000–2026 represented 35 trials and 2,580 randomized participants; 34 trials contributed quantitative data. Versus metformin, combination therapy lowered HOMA-IR (MD −0.91, 95% CI −1.22 to −0.60) and free androgen index (MD −2.46, −3.97 to −0.96), and increased SHBG (MD 10.21 nmol/L, 6.54–13.89). Ovulation favored combination therapy (OR 16.12, 95% CI 2.87–90.63), but was source-sensitive; pregnancy comparisons remained imprecise. Of 186 comparisons, certainty was moderate for 15, low for 21, and very low for 150. No meta-regression association survived multiplicity adjustment. MR associated genetically proxied GLP1R expression with lower total testosterone (β −0.049, 95% CI −0.076 to −0.022), lower bioavailable testosterone, and higher SHBG. Conclusions: Combination therapy may improve selected short-term metabolic and androgen-related measures in women with PMOS and overweight or obesity. Genetic findings provide complementary evidence linking genetically proxied GLP1R expression to androgen-related traits. Larger, longer-term trials are needed to determine whether these changes translate into reproductive and patient-important benefits.